For oral contraceptive users, coagulation monitoring (factor VIII, vWF, APC resistance) may identify high‐risk individuals, while obesity management—focused on reducing inflammatory states and improving coagulation factor profiles—represents a key preventive strategy (Zuurbier et al. This evidence concerns the gene VWF and obesity due to melanocortin 4 receptor deficiency.